Abstract
The indole-substituted titanocene dichloride derivative Titanocene T, which is completely water-soluble and shows micromolar activity against the human renal cancer cells Caki-1, was tested in vivo an against xenografted human renal cell tumors in mice. Titanocene T was then given at 25 and 50 mg/kg, seven times every four days during three weeks to two groups (n=6) of Caki-1 tumor-bearing female NMRI:nu/nu mice, while the control group was treated with solvent only. At both doses Titanocene T induced a moderate to good tumor growth reduction with respect to the solventtreated control group, with an optimal T/C value of 51% and 32% and showed neither mortality nor toxicity. Immunohistochemical analysis revealed that the expression of the proliferation marker Ki-67 was reduced in the high-dosage group. Furthermore, anti-angiogenic activity was identified by CD31 staining; the number of micro vessels in a defined tumor area decreased by 27% and 29% due to Titanocene T treatment.
Keywords: Anticancer drug, anti-angiogenic drug, Titanocene, Renal cell cancer, Xenograft
Letters in Drug Design & Discovery
Title:The Activity of Titanocene T Against Xenografted Caki-1 Tumors
Volume: 10 Issue: 5
Author(s): Wolfgang Walther, Iduna Fichtner, Anthony Deally, Megan Hogan and Matthias Tacke
Affiliation:
Keywords: Anticancer drug, anti-angiogenic drug, Titanocene, Renal cell cancer, Xenograft
Abstract: The indole-substituted titanocene dichloride derivative Titanocene T, which is completely water-soluble and shows micromolar activity against the human renal cancer cells Caki-1, was tested in vivo an against xenografted human renal cell tumors in mice. Titanocene T was then given at 25 and 50 mg/kg, seven times every four days during three weeks to two groups (n=6) of Caki-1 tumor-bearing female NMRI:nu/nu mice, while the control group was treated with solvent only. At both doses Titanocene T induced a moderate to good tumor growth reduction with respect to the solventtreated control group, with an optimal T/C value of 51% and 32% and showed neither mortality nor toxicity. Immunohistochemical analysis revealed that the expression of the proliferation marker Ki-67 was reduced in the high-dosage group. Furthermore, anti-angiogenic activity was identified by CD31 staining; the number of micro vessels in a defined tumor area decreased by 27% and 29% due to Titanocene T treatment.
Export Options
About this article
Cite this article as:
Walther Wolfgang, Fichtner Iduna, Deally Anthony, Hogan Megan and Tacke Matthias, The Activity of Titanocene T Against Xenografted Caki-1 Tumors, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050002
DOI https://dx.doi.org/10.2174/1570180811310050002 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
Current Pharmaceutical Design Evaluation of Cytotoxic and Tyrosinase Inhibitory Activities of 2-phenoxy(thiomethyl) pyridotriazolopyrimidines: In Vitro and Molecular Docking Studies
Anti-Cancer Agents in Medicinal Chemistry Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets First Ayurvedic Approach Towards Green Drugs: Anti Cervical Cancer-Cell Properties of Clerodendrum viscosum Root Extract
Anti-Cancer Agents in Medicinal Chemistry Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) N-Aryl-5-aminopyrazole: A Versatile Architecture in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds
Current Drug Metabolism Graphene and Graphene Oxide as a Docking Station for Modern Drug Delivery System
Current Drug Delivery Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism The Use of Intravenous Aminobisphosphonates for the Treatment of Pagets Disease of Bone
Mini-Reviews in Medicinal Chemistry What is the Current Role of Immunotherapy for Colon Cancer?
Reviews on Recent Clinical Trials Selecting Patients with Small Renal Masses for Active Surveillance
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Current and Future Therapy for Chronic Hepatitis C Virus Liver Disease
Current Drug Targets - Infectious Disorders Peptides in Oral Diseases
Current Pharmaceutical Design FOXO1: A Potential Target for Human Diseases
Current Drug Targets